Janssen-Pharmacyclics lymphoma drug gets breakthrough status

02/15/2013 | PharmaTimes (U.K.)

The FDA granted breakthrough therapy status to Janssen Biotech and Pharmacyclics' ibrutinib, a Bruton's tyrosine kinase inhibitor, as a treatment for relapsed or refractory mantle cell lymphoma and Waldenström's macroglobulinemia. The companies plan to submit the drug for approval for mantle cell lymphoma in 2013.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY